or Try an Advanced Search...

    Technical Analysis for BEAM - Beam Therapeutics Inc.

    Grade Last Price % Change Price Change
    F 21.55 -2.44% -0.54
    BEAM closed down 2.44 percent on Friday, October 25, 2024, on 2.39 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Nov 6
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical BEAM trend table...
    Date Alert Name Type % Chg
    180 Bearish Setup Bearish Swing Setup 0.00%
    Slingshot Bearish Bearish Swing Setup 0.00%
    Stochastic Buy Signal Bullish 0.00%
    Oversold Stochastic Weakness 0.00%
    Hammer Candlestick Bullish -2.44%
    Lizard Bullish Bullish Day Trade Setup -2.44%
    Calm After Storm Range Contraction -2.44%
    Doji - Bullish? Reversal -2.44%
    Lower Bollinger Band Touch Weakness -2.44%
    Oversold Stochastic Weakness -2.44%
    Older End-of-Day Signals for BEAM ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % 2 days ago
    60 Minute Opening Range Breakdown 2 days ago
    Possible NR7 2 days ago
    Up 1% 2 days ago
    60 Minute Opening Range Breakout 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    BEAM Chart by TradingView
    Basic chart:

    Profile

    Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. The company was founded in 2017 and is based in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Gene Therapy Acute Myeloid Leukemia Leukemia Central Nervous System Disorders Nervous System Disorders Antitrypsin Deficiency Sickle Cell Disease Acute Leukemia Acute Lymphoblastic Leukemia Thalassemia Beta Thalassemia Glycogen Storage Disorder

    Is BEAM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 23 Beam Therapeutics (BEAM): A Small-Cap Leader in Precision Genetic Medicine
    Oct 17 State Street Corp's Strategic Acquisition in Beam Therapeutics Inc
    Sep 29 Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy
    Sep 5 Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
    Aug 14 Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine with CRISPR Technology
    Aug 9 3 Gene Editing Stocks with Potential to Transform Medicine
    Aug 8 Beam Therapeutics Second Quarter 2024 Earnings: Revenues Disappoint
    Aug 7 Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
    Aug 6 Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
    Aug 6 Beam Therapeutics GAAP EPS of -$1.11 beats by $0.01, revenue of $11.77M misses by $1.28M
    See more BEAM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 49.5
    52 Week Low 18.18
    Average Volume 820,726
    200-Day Moving Average 26.82
    50-Day Moving Average 24.58
    20-Day Moving Average 23.73
    10-Day Moving Average 23.90
    Average True Range 1.22
    RSI (14) 36.31
    ADX 15.74
    +DI 18.82
    -DI 28.67
    Chandelier Exit (Long, 3 ATRs) 23.76
    Chandelier Exit (Short, 3 ATRs) 24.79
    Upper Bollinger Bands 26.55
    Lower Bollinger Band 20.90
    Percent B (%b) 0.11
    BandWidth 23.82
    MACD Line -0.65
    MACD Signal Line -0.35
    MACD Histogram -0.2988
    Fundamentals Value
    Market Cap 1.76 Billion
    Num Shares 81.5 Million
    EPS -4.17
    Price-to-Earnings (P/E) Ratio -5.17
    Price-to-Sales 29.03
    Price-to-Book 3.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.78
    Resistance 3 (R3) 22.90 22.61 22.58
    Resistance 2 (R2) 22.61 22.30 22.55 22.51
    Resistance 1 (R1) 22.08 22.10 21.94 21.96 22.44
    Pivot Point 21.79 21.79 21.72 21.73 21.79
    Support 1 (S1) 21.26 21.48 21.12 21.14 20.66
    Support 2 (S2) 20.97 21.28 20.91 20.59
    Support 3 (S3) 20.44 20.97 20.53
    Support 4 (S4) 20.32